NEW YORK (AVAFIN) -- Options traders were heavily trading call contracts during the last trading session establishing a
new 3-month call volume record. A total of 12,461 put and 39,016 calls were traded where call
contracts outnumbered puts 3.1:1, yielding a 0.32 ratio.
The skewed options ratio suggests that traders are re-balancing their portfolios in anticipation
of a price shift. Unusual volume activity directly reflects investor outlook and confirms that a
stock move is imminent.
Teva's oral multiple sclerosis drug, laquinimod, failed to meet clinical endpoints in its second Phase III trial and appears to be less effective than competing compounds from Novartis and Biogen Idec.
Additionaly, Teva faces considerable competition from low-cost producers in India and China. Aggressive entry pricing could weaken Teva's dominant market position.
Teva Pharmaceutical Industries settled the day down $0.64 to $43.86 in the previous trading session. Today's
trading range was between $43.70 and $44.96 respectively. On the volume side, 4M shares were
traded, which is greater than the average volume of 4M shares. TEVA is trading
below the 50 day moving average and higher than the 200 day
moving average. The stock's 52 week low is $35.00 and 52 week high is $51.15. To date, the stock has lost -3.77% within the last week.
The stock has a P/E ratio of 14.40 and a dividend yield of 2.14%.
Teva Pharmaceutical Industries Ltd is a global pharmaceutical company that develops, produces and markets generic drugs covering all major treatment categories.